前列腺癌具有可变的自然史，尽管存在生化复发（BCR）预测因子，但它们在预测结果方面仍然有限。  睾酮在晚期前列腺癌中的作用众所周知，但其在局限性前列腺癌中的作用仍不确定。  在本研究中，我们评估了接受根治性耻骨后前列腺切除术（RRP）的患者中睾酮水平和雄激素受体（AR）表达与肿瘤和功能结果的关系。  通过一项回顾性研究，对接受 RRP 且术前至少服用两次总睾酮剂量的患者，根据睾酮水平、肿瘤学和功能结果进行分析和比较。  分析数据后，在生物样本库中选择组织样本进行 AR 和 AR-V7 表达。  应用排除标准后，212 名患者被纳入分析。  32 名患者 (15.1%) 睾酮水平较低，并且在该组中，24 个月时观察到勃起功能恢复率较低（53.1% vs. 71.7%；p = 0.037），BCR 率较高（21.9 % vs. 9.4%；p = 0.041) 和更高的国际泌尿病理学会 (ISUP) 活检产品等级。  低睾酮患者的 AR 表达较高，但复发率没有差异。  睾酮水平较低与 RRP 后 24 个月结束时勃起功能恢复率较低有关，此外还导致活检中较高的 BCR 率和较高的 ISUP 等级。  此外，总睾酮<300 ng/dL的患者AR表达较高，但BCR率没有差异。

  Prostate cancer has a variable natural history and, despite the existence of biochemical recurrence (BCR) predictors, they are still limited in predicting outcomes.  The role of testosterone in advanced prostate cancer is well known, however its role in localized prostate cancer is still uncertain.  In the present study, we evaluated the relationship of testosterone levels and androgen receptor (AR) expression with oncological and functional outcomes, in patients undergoing radical retropubic prostatectomy (RRP).  Through a retrospective study, patients who underwent RRP, who had at least two preoperative total testosterone dosages, were analyzed and compared according to testosterone levels, oncological and functional outcomes.  After analyzing data, tissue samples were selected in a biorepository to carry out the AR and the AR-V7 expression.  After applying exclusion criteria, 212 patients were included in the analysis.  Thirty-two patients (15.1%) had low testosterone levels and, in this group, a lower rates of erectile function recovery were observed at 24 months (53.1% vs. 71.7%; p = 0.037), a higher rate of BCR (21.9% vs. 9.4%; p = 0.041) and higher International Society of Urological Pathology (ISUP) grade in biopsy products.  The AR expression was higher in patients with low testosterone, but there was no difference in relapse rates.  Lower levels of testosterone were related to lower rates of erectile function recovery at the end of 24 months after RRP, in addition to conferring higher rates of BCR and higher ISUP grades in biopsy.  Furthermore, patients with total testosterone < 300 ng/dL had higher expression of AR, but no difference in BCR rates.